{"filing":{"accession_number":"0001178913-26-003796","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"zk2635818.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/zk2635818.htm"},"events":[{"id":23857,"run_id":21578,"accession_number":"0001178913-26-003796","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Silexion disclosed positive preclinical research findings for its lead candidate SIL204 demonstrating multi-mechanism immune sensitization in KRAS-driven cancers. While this is a research milestone rather than a clinical trial result or earnings release, it represents material operational progress for a clinical-stage biotech company advancing toward Phase 2/3 evaluation. The disclosure emphasizes the scientific rationale for combination therapy and the company's clinical advancement, making it operationally significant to investors assessing the company's pipeline and therapeutic potential.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24206,"accession_number":"0001178913-26-003796","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Silexion disclosed positive preclinical research findings for its lead candidate SIL204 demonstrating multi-mechanism immune sensitization in KRAS-driven cancers. While this is a research milestone rather than a clinical trial result or earnings release, it represents material operational progress for a clinical-stage biotech company advancing toward Phase 2/3 evaluation. The disclosure emphasizes the scientific rationale for combination therapy and the company's clinical advancement, making it operationally significant to investors assessing the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:48.951781+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24206,"accession_number":"0001178913-26-003796","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Silexion disclosed positive preclinical research findings for its lead candidate SIL204 demonstrating multi-mechanism immune sensitization in KRAS-driven cancers. While this is a research milestone rather than a clinical trial result or earnings release, it represents material operational progress for a clinical-stage biotech company advancing toward Phase 2/3 evaluation. The disclosure emphasizes the scientific rationale for combination therapy and the company's clinical advancement, making it operationally significant to investors assessing the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:48.951781+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-04"}]}